Jacob Van Naarden (Eli Lilly)
September 20, 2021 01:15 PM EDTUpdated 02:06 PM
Bioregnum

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

Paul Schloesser

Associate Editor

John Carroll

Editor & Founder

It’s tak­en 7 years, but Eli Lil­ly is promis­ing to fi­nal­ly start ham­mer­ing the small and af­flu­ent PD-(L)1 club with a “dis­rup­tive” pric­ing strat­e­gy for …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

SV Health’s $269M de­men­tia fund; Schrödinger lays off 7% of staff

Ge­of­frey Porges ex­its Schrödinger with CFO swap; A new board seat for As­traZeneca's Pas­cal So­ri­ot

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

GSK kicks off Blenrep re­launch plans with clear­ance from UK reg­u­la­tors

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times